-
近年来我国糖尿病病人的数量位居世界第一。超重和肥胖是糖尿病的发病原因之一,人群逐年上升。糖尿病大血管病变是2型糖尿病(T2DM)致残致死的主要原因。糖尿病大血管病变的发生和肥胖密切相关,脂肪细胞分泌的脂肪细胞因子可能是二者的纽带。研究[1]显示,脂肪因子与糖尿病血管并发症的发生、发展密切相关。近年来发现的脂肪细胞因子趋化素,可通过多种途径参与糖脂代谢, 对脂肪组织的形成具有调节功能。因此,本研究观察T2DM病人血清趋化素水平与糖尿病大血管病变的相关指标的相关性,为早期发现,早期诊断,早期治疗糖尿病大血管病变提供思路。
-
CIMT增厚组与CIMT正常组的年龄、TC、TG、FINS、HOMA-IR、舒张压(DBP)、收缩压(SBP)、VFA、趋化素、SFA差异均有统计学意义(P < 0.01)(见表 1)。
分组 n 趋化素/(pg/mL) VFA/cm2 HOMA-IR TG/(mmol/L) TC/(mmol/L) CIMT正常组 55 48.35±6.25 79.89±19.35 7.80±2.77 1.49±0.98 3.47±0.82 CIMT增厚组 62 57.77±5.54 136.51±25.01 13.85±5.11 2.32±1.84 4.14±1.15 t — 8.64 13.78 8.04 3.11 3.68 P — < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 分组 n 年龄/岁 DBP/mmHg SBP/mmHg FINS/(mIL/L) SFA/cm2 CIMT正常组 55 53.45±13.11 73.23±8.42 122.64±14.72 9.73±4.83 175.59±28.93 CIMT增厚组 62 60.37±11.63 80.03±9.63 137.22±16.72 17.70±7.91 209.04±28.69 t — 3.03 4.05 4.98 6.66 6.27 P — < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 表 1 CIMT正常组与CIMT增厚组观察指标比较(x±s)
-
腹型肥胖组TC、TG、HOMA-IR、DBP、SBP、SFA、趋化素、CIMT高于非腹型肥胖组,差异均有统计学意义(P < 0.05)(见表 2)。
分组 n HOMA-IR 趋化素/(pg/mL) SFA/cm2 CIMT/mm 非腹型肥胖组 68 9.28±4.71 48.54±5.28 170.66±20.51 0.87±0.53 腹型肥胖组 49 13.36±4.80 60.00±4.50 224.75±18.56 1.21±0.53 t — 4.58 12.30 14.64 3.45 P — < 0.01 < 0.01 < 0.01 < 0.01 分组 n TG/(mmol/L) TC/(mmol/L) SBP/mmHg DBP/mmHg 非腹型肥胖组 68 1.51±1.00 3.64±0.92 127.17±15.34 73.95±8.59 腹型肥胖组 49 2.51±1.95 4.09±1.18 134.80±19.12 80.84±9.73 t — 3.30 2.26 2.39 4.05 P — < 0.01 < 0.05 < 0.05 < 0.01 表 2 腹型肥胖组与非腹型肥胖组观察指标比较(x±s)
-
相关性分析结果显示:2型糖尿病病人血清趋化素与SBP、DBP、TC、TG、BMI、FINS、HOMA-IR、VFA、SFA、CIMT均呈正相关关系(r=0.277、0.303、0.295、0.299、0.567、0.317、0.380、0.795、0.903、0.565,P < 0.01)(见表 3)。
相关系数 CIMT VFA HOMA-IR TC TG SBP DBP FINS SFA BMI r 0.565 0.795 0.380 0.295 0.299 0.277 0.303 0.317 0.903 0.567 P < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 表 3 趋化素与各观察指标的相关性
-
以CIMT为因变量,以各指标为自变量,进行logistic回归分析,结果显示,VFA、趋化素、SFA、FINS是CIMT的可能影响因素(P < 0.05~P < 0.01)(见表 4)。
变量 B SE P OR 95%CI VFA/cm2 0.076 0.028 0.007 1.076 1.022~1.140 FINS/(mIL/L) 0.167 0.080 0.036 1.182 1.011~1.382 趋化素/(pg/mL) 0.259 0.118 0.028 1.295 1.028~1.633 SFA/cm2 -0.053 0.024 0.026 0.948 0.904~0.994 表 4 CIMT影响因素的logistic回归分析
-
以VFA为因变量,以各指标为自变量,进行logistic回归分析,结果显示,趋化素、SFA、HOMA-IR、CIMT是VFA的可能影响因素(P < 0.05)(见表 5)。
变量 B SE P OR 95%CI 趋化素/(pg/mL) 0.341 0.154 0.027 1.407 1.040~1.903 SFA/cm2 0.094 0.030 0.002 1.098 1.035~1.165 HOMA-IR 0.326 0.136 0.017 1.385 1.060~1.809 CIMT/mm -2.950 1.496 0.049 0.052 0.003~0.981 表 5 VFA影响因素的logistic二元回归分析
2型糖尿病病人血清趋化素水平与腹型肥胖及大血管病变的关系
Relationship among serum chemerin level, abdominal obesity and diabetic macroangiopathy in patients with type 2 diabetes mellitus
-
摘要:
目的探讨2型糖尿病(T2DM)病人血清趋化素水平与动脉粥样硬化发生发展的关系。 方法选取T2DM病人117例,根据颈动脉内中膜厚度(CIMT)分组,分为CIMT正常组55例和CIMT增厚组62例;根据内脏脂肪面积(VFA)分组,分为腹型肥胖组49例和非腹型肥胖组68例。所有研究对象记录体质量指数(BMI)、收缩压(SBP)、舒张压(DBP);检测空腹血糖(FBS)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、C反应蛋白(CRP)等;采用酶联免疫吸附法测定血清趋化素浓度,采用生物电阻抗测试法测量腹部内脏脂肪面积(VFA)和腹部皮下脂肪面积(SFA)。比较2组之间观察指标的差异,Pearson相关分析血清趋化素水平与各观察指标的相关性,二元logistics回归分析VFA、CIMT增厚的相关因素。 结果与CIMT正常组比较,CIMT增厚组TC、TG、FINS、HOMA-IR、DBP、SBP、VFA、趋化素、SFA均升高(P < 0.01);与非腹型肥胖组比较,腹型肥胖组TC、TG、HOMA-IR、DBP、SBP、SFA、趋化素、CIMT均升高(P < 0.05)。相关分析结果显示,T2DM病人血清趋化素与SBP、DBP、TC、TG、BMI、FINS、HOMA-IR、VFA、SFA、CIMT均呈正相关关系(r=0.277、0.303、0.295、0.299、0.567、0.317、0.380、0.795、0.903、0.565,P < 0.01)。二元logistic回归分析结果显示,VFA、趋化素、FINS、SFA是CIMT的影响因素(P < 0.05~P < 0.01);趋化素、SFA、HOMA-IR、CIMT是VFA的独立影响因素(P < 0.05)。 结论趋化素能够促进T2DM病人CIMT增厚,是一种危险因素,参与T2DM病人动脉粥样硬化的发生、发展。 Abstract:ObjectiveTo explore the relationship between serum chemerin level in patients with type 2 diabetes mellitus(T2DM) and the development and progression of atherosclerosis. MethodsA total of 117 T2DM patients were selected.Based on carotid intima-media thickness(CIMT), they were divided into CIMT normal group(n=55) and CIMT thickening group(n=62).Based on visceral fat area(VFA), all the patients were divided into was divided into the abdominal obesity group(n=49), and non-abdominal obesity group(n=68).All study subjects had been recorded including their body mass index(BMI), systolic blood pressure(SBP), diastolic blood pressure(DBP).Moreover, fasting blood glucose(FBS), fasting insulin(FINS), triglycerides(TG), total cholesterol(TC), low-density lipoprotein-cholesterol(LDL-C), high-density lipoprotein-cholesterol(HDL-C), glycosylated hemoglobin(HbA1c), C-reactive protein(CRP) and other indicators were detected.Furthermore, the serum chemerin concentrations were determined by the enzyme-linked immunosorbent assay, and the abdominal VFA and abdominal subcutaneous fat area(SFA) were measured by the bio-electrical inpedance analysis method.The differences of observation indexes between the two groups were compared.Pearson correlation analysis was conducted to explore the correlation between serum chemerin levels and the observation indexes.Binary logistics regression analysis was performed on the related factors of VFA and CIMT thickening. ResultsCompared with the CIMT normal group, the TC, TG, FINS, HOMA-IR, DBP, SBP, VFA, chemerin and SFA were all increased in the CIMT thickening group(P < 0.01).Compared with the non-abdominal obesity group, TC, TG, HOMA-IR, DBP, SBP, SFA, chemerin and CIMT was increased in the abdominal obesity group(P < 0.05).The results of correlation analysis showed that serum chemerin levels in patients with T2DM were positively correlated with SBP, DBP, TC, TG, BMI, FINS, HOMA-RI, VFA, SFA and CIMT(r=0.277, 0.303, 0.295, 0.299, 0.567, 0.317, 0.380, 0.795, 0.903, 0.565, P < 0.01).The results of binary logistic regression analysis showed that VFA, chemerin, FINS and SFA were the related factors of CIMT(P < 0.05 to P < 0.01);chemerin, SFA, HOMA-IR and CIMT were the related factors of VFA(P < 0.05). ConclusionsChemerin can promote the thickening of CIMT in patients with T2DM, which is a risk factor participating in the occurrence and development of atherosclerosis for patients with T2DM. -
Key words:
- type 2 diabetes mellitus /
- chemerin /
- carotid intima-media thickness /
- visceral fat area
-
表 1 CIMT正常组与CIMT增厚组观察指标比较(x±s)
分组 n 趋化素/(pg/mL) VFA/cm2 HOMA-IR TG/(mmol/L) TC/(mmol/L) CIMT正常组 55 48.35±6.25 79.89±19.35 7.80±2.77 1.49±0.98 3.47±0.82 CIMT增厚组 62 57.77±5.54 136.51±25.01 13.85±5.11 2.32±1.84 4.14±1.15 t — 8.64 13.78 8.04 3.11 3.68 P — < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 分组 n 年龄/岁 DBP/mmHg SBP/mmHg FINS/(mIL/L) SFA/cm2 CIMT正常组 55 53.45±13.11 73.23±8.42 122.64±14.72 9.73±4.83 175.59±28.93 CIMT增厚组 62 60.37±11.63 80.03±9.63 137.22±16.72 17.70±7.91 209.04±28.69 t — 3.03 4.05 4.98 6.66 6.27 P — < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 表 2 腹型肥胖组与非腹型肥胖组观察指标比较(x±s)
分组 n HOMA-IR 趋化素/(pg/mL) SFA/cm2 CIMT/mm 非腹型肥胖组 68 9.28±4.71 48.54±5.28 170.66±20.51 0.87±0.53 腹型肥胖组 49 13.36±4.80 60.00±4.50 224.75±18.56 1.21±0.53 t — 4.58 12.30 14.64 3.45 P — < 0.01 < 0.01 < 0.01 < 0.01 分组 n TG/(mmol/L) TC/(mmol/L) SBP/mmHg DBP/mmHg 非腹型肥胖组 68 1.51±1.00 3.64±0.92 127.17±15.34 73.95±8.59 腹型肥胖组 49 2.51±1.95 4.09±1.18 134.80±19.12 80.84±9.73 t — 3.30 2.26 2.39 4.05 P — < 0.01 < 0.05 < 0.05 < 0.01 表 3 趋化素与各观察指标的相关性
相关系数 CIMT VFA HOMA-IR TC TG SBP DBP FINS SFA BMI r 0.565 0.795 0.380 0.295 0.299 0.277 0.303 0.317 0.903 0.567 P < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 表 4 CIMT影响因素的logistic回归分析
变量 B SE P OR 95%CI VFA/cm2 0.076 0.028 0.007 1.076 1.022~1.140 FINS/(mIL/L) 0.167 0.080 0.036 1.182 1.011~1.382 趋化素/(pg/mL) 0.259 0.118 0.028 1.295 1.028~1.633 SFA/cm2 -0.053 0.024 0.026 0.948 0.904~0.994 表 5 VFA影响因素的logistic二元回归分析
变量 B SE P OR 95%CI 趋化素/(pg/mL) 0.341 0.154 0.027 1.407 1.040~1.903 SFA/cm2 0.094 0.030 0.002 1.098 1.035~1.165 HOMA-IR 0.326 0.136 0.017 1.385 1.060~1.809 CIMT/mm -2.950 1.496 0.049 0.052 0.003~0.981 -
[1] LACHINE NA, ELNEKIEDY AA, MEGALLAA MH, et al. Serum chemerin and high-sensitivity C reactive protein as markers of subclinical atherosclerosis in Egyptian patients with type 2 diabetes[J]. Ther Adv Endocrinol Metab, 2016, 7(2): 47. doi: 10.1177/2042018816637312 [2] ROMAN AA, PARLEE S D, SINAL CJ. Chemerin: a potential endocrine link between obesity and type 2 diabetes[J]. Endocrine, 2012, 42(2): 243. doi: 10.1007/s12020-012-9698-8 [3] TAN BK, CHEN J, FARHATULLAH S, et al. Insulin and metformin regulate circulating and adipose tissue chemerin[J]. Diabetes, 2009, 58(9): 1971. doi: 10.2337/db08-1528 [4] SELL H, ECKEL J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation?[J]. Proc Nutr Soc, 2009, 68(4): 378. doi: 10.1017/S0029665109990218 [5] DAUDT LD, MUSSKOPF ML, MENDEZ M. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis[J]. PLoS One, 2014, 9(12): e113915. doi: 10.1371/journal.pone.0113915 [6] CHAKAROUN R, RASCHPICHLER M, KLÖTING N, et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity[J]. Metabolism, 2012, 61(5): 706. doi: 10.1016/j.metabol.2011.10.008 [7] PARLEE SD, ERNST MC, MURUGANANDAN S, et al. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-α[J]. Endocrinology, 2010, 151(6): 2590. doi: 10.1210/en.2009-0794 [8] SONNENBERG GE, KRAKOWER GR, KISSEBAH AH. A novel pathway to the manifestations of metabolic syndrome[J]. Obesity Res, 2004, 12(2): 180. doi: 10.1038/oby.2004.24 [9] BOZAOGLU K, BOLTON K, MCMILLAN J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome[J]. Endocrinology, 2007, 148(10): 4687. doi: 10.1210/en.2007-0175 [10] 王玲艳, 于浩泳, 魏丽. 脂肪组织chemerin及其受体chemerinR基因表达与肥胖及2型糖尿病的关系[J]. 上海交通大学学报(医学版), 2017, 37(3): 352. doi: 10.3969/j.issn.1674-8115.2017.03.014 [11] 刘俊田. 动脉粥样硬化发病的炎症机制的研究进展[J]. 西安交通大学学报(医学版), 2015, 36(2): 141.